KALA BIO Statistics
Total Valuation
KALA BIO has a market cap or net worth of $31.23 million. The enterprise value is $22.47 million.
| Market Cap | 31.23M |
| Enterprise Value | 22.47M |
Important Dates
The next estimated earnings date is Friday, August 7, 2026, before market open.
| Earnings Date | Aug 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
KALA BIO has 18.59 million shares outstanding. The number of shares has increased by 3,212.14% in one year.
| Current Share Class | 18.59M |
| Shares Outstanding | 18.59M |
| Shares Change (YoY) | +3,212.14% |
| Shares Change (QoQ) | +4,580.47% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 0.65% |
| Float | 18.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.90 |
| P/TBV Ratio | 2.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.91
| Current Ratio | 7.91 |
| Quick Ratio | 5.68 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.36 |
Financial Efficiency
Return on equity (ROE) is -238.68% and return on invested capital (ROIC) is -85.94%.
| Return on Equity (ROE) | -238.68% |
| Return on Assets (ROA) | -69.26% |
| Return on Invested Capital (ROIC) | -85.94% |
| Return on Capital Employed (ROCE) | -311.89% |
| Weighted Average Cost of Capital (WACC) | -8.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.28M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -99.31% in the last 52 weeks. The beta is -2.38, so KALA BIO's price volatility has been lower than the market average.
| Beta (5Y) | -2.38 |
| 52-Week Price Change | -99.31% |
| 50-Day Moving Average | 3.43 |
| 200-Day Moving Average | 64.39 |
| Relative Strength Index (RSI) | 31.65 |
| Average Volume (20 Days) | 171,639 |
Short Selling Information
The latest short interest is 64,883, so 0.35% of the outstanding shares have been sold short.
| Short Interest | 64,883 |
| Short Previous Month | 70,709 |
| Short % of Shares Out | 0.35% |
| Short % of Float | 0.35% |
| Short Ratio (days to cover) | 0.70 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -33.56M |
| Pretax Income | -19.65M |
| Net Income | -19.65M |
| EBITDA | -33.23M |
| EBIT | -33.56M |
| Earnings Per Share (EPS) | -$6.34 |
Balance Sheet
The company has $8.76 million in cash and n/a in debt, with a net cash position of $8.76 million or $0.47 per share.
| Cash & Cash Equivalents | 8.76M |
| Total Debt | n/a |
| Net Cash | 8.76M |
| Net Cash Per Share | $0.47 |
| Equity (Book Value) | 10.76M |
| Book Value Per Share | 0.58 |
| Working Capital | 10.76M |
Cash Flow
In the last 12 months, operating cash flow was -$26.06 million and capital expenditures -$15,000, giving a free cash flow of -$26.08 million.
| Operating Cash Flow | -26.06M |
| Capital Expenditures | -15,000 |
| Depreciation & Amortization | 328,250 |
| Net Borrowing | -22.48M |
| Free Cash Flow | -26.08M |
| FCF Per Share | -$1.40 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
KALA BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3,212.14% |
| Shareholder Yield | -3,212.14% |
| Earnings Yield | -62.93% |
| FCF Yield | -83.50% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 11, 2026. It was a reverse split with a ratio of 1:50.
| Last Split Date | May 11, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:50 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |